Impact of recent IP caselaw on biomarkers and personalized medicine

ISSN： 1478-565X

Source： Journal of Commercial Biotechnology, Vol.17, Iss.2, 2011-05, pp. : 191-194

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Personalized medicine and oncology: A commentary and key questions

By Freeman Robert

Journal of Commercial Biotechnology, Vol. 16, Iss. 3, 2010-07 ,pp. : 197-200

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Personalized medicine: revolutionizing drug discovery and patient care

By Ginsburg G.S. McCarthy J.J.

Trends in Biotechnology, Vol. 19, Iss. 12, 2001-12 ,pp. : 491-496

Elsevier

Access to resources Recommend Favorite

Using IP audits to optimize IP assets

By Cullem James G

Journal of Commercial Biotechnology, Vol. 16, Iss. 1, 2010-01 ,pp. : 88-93

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Graphene nanomaterials as biocompatible and conductive scaffolds for stem cells: impact for tissue engineering and regenerative medicine

Journal Of Tissue Engineering And Regenerative Medicine, Vol. 9, Iss. 12, 2015-12 ,pp. : 1321-1338

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: Biomarkers – The kiss of death

By Krueger Todd

Journal of Commercial Biotechnology, Vol. 11, Iss. 2, 2005-01 ,pp. : 109-110

Palgrave Macmillan Ltd

Access to resources Recommend Favorite